首頁 > 市場調查報告書 > 製藥

非專利藥糖尿病生物製劑生技仿製藥

市場調查報告書

商品編碼

1629226

甘精胰島素市場，按類型、糖尿病類型、配銷通路、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Insulin Glargine Market, By Type, By Diabetes Type, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日期: 2024年12月04日 | 出版商:

AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

報告要點

2023年甘精胰島素市場規模為18.2098億美元，2024年至2032年複合年成長率為6.50%。

甘精胰島素市場-市場動態

全球糖尿病發生率上升推動市場需求

全球甘精胰島素市場受到第 2 型糖尿病盛行率上升的推動，全球有 5.37 億成年人被診斷出患有第 2 型糖尿病。不斷成長的老年人口進一步增加了對胰島素治療的需求。機會來自政府的醫療保健舉措和生物學名藥的可用性。此外，更先進的胰島素輸送系統（例如智慧胰島素筆和胰島素幫浦）的開發為甘精胰島素的管理提供了更方便、更精確的方法。然而，複雜的製造流程和供應鏈中斷（例如半導體短缺）阻礙了成長。

甘精胰島素市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 6.50% 左右的複合年成長率成長

根據類型細分，來得時預計將在 2023 年展現最大市場佔有率

根據糖尿病類型細分，2023年第二型糖尿病是主導細分市場

按地區分類，北美是 2023 年的主要收入來源

甘精胰島素市場-細分分析：

全球甘精胰島素市場根據類型、糖尿病類型、分銷管道和地區進行細分。

市場依類型分為三類：basaglar、lantus、soliqua/suliqua、toujeo 等。來得時產業在市場上佔據主導地位。這主要是由於其作為長效胰島素溶液的既定功效以及廣泛的患者和醫生的偏好。廣泛的臨床應用和強大的品牌認知度進一步支持了其受歡迎程度。

市場依糖尿病類型分為兩類：第1型糖尿病和第2型糖尿病。 2 類產業在市場中佔據主導地位，並可能在預測期內保持其主導地位。這一成長是由全球 2 型糖尿病患病率上升推動的，人口老化、城市化和生活方式改變等因素推動了這一成長。

甘精胰島素市場 - 地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太地區以及中東和非洲地區。這些區域根據開展業務的國家進一步分類。

甘精胰島素市場-競爭格局：

由於對長效胰島素解決方案的需求不斷成長，甘精胰島素市場正在擴大。公司正致力於改進產品配方，以提高患者的依從性並最大限度地減少副作用。此外，競爭策略包括建立夥伴關係和合作以擴大分銷網路，以及投資生物相似藥開發以提供具有成本效益的替代品。一些公司還專注於數位健康整合，以提供全面的糖尿病管理解決方案，以長期用戶參與為目標。

介紹
- 按地理位置分類的細分市場佔有率分析
北美洲
- 概述
- 北美甘精胰島素主要製造商
- 北美市場規模和預測（按國家）
- 北美市場規模和預測（按類型）
- 北美市場規模與預測（按糖尿病類型）
- 北美市場規模和預測（按配銷通路）
- 美國
- 加拿大
歐洲
- 概述
- 歐洲甘精胰島素主要製造商
- 歐洲市場規模和預測（按國家）
- 歐洲市場規模與預測（按類型）
- 歐洲市場規模與預測（按糖尿病類型）
- 歐洲市場規模和預測（按配銷通路）
- 德國
- 義大利
- 英國
- 法國
- 俄羅斯
- 荷蘭
- 瑞典
- 波蘭
- 歐洲其他地區
亞太地區 (APAC)
- 概述
- 亞太地區甘精胰島素主要製造商
- 亞太地區市場規模與預測（按國家）
- 亞太地區市場規模與預測（按類型）
- 按糖尿病類型分類的亞太地區市場規模和預測
- 亞太地區市場規模和預測（按配銷通路）
- 印度
- 中國
- 日本
- 韓國
- 澳洲
- 泰國
- 印尼
- 菲律賓
- 亞太地區其他地區
拉丁美洲
- 概述
- 拉丁美洲甘精胰島素主要製造商
- 拉丁美洲市場規模與預測（按國家）
- 拉丁美洲市場規模與預測（按類型）
- 拉丁美洲市場規模與預測（按糖尿病類型）
- 拉丁美洲市場規模和預測（按配銷通路）
- 巴西
- 墨西哥
- 阿根廷
- 哥倫比亞
- 拉丁美洲其他地區
中東和非洲
- 概述
- 中東和非洲甘精胰島素主要製造商
- 中東和非洲市場規模及預測（按國家）
- 中東和非洲市場規模及預測（按類型）
- 中東和非洲市場規模及預測（按糖尿病類型）
- 中東和非洲市場規模及預測（按配銷通路）
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 土耳其
- 阿爾及利亞
- 埃及
- MEA 的其餘部分

第 11 章：主要供應商分析 - 甘精胰島素產業

競爭儀表板
- Competitive Benchmarking
- Competitive Positioning
公司簡介
- Amigoz Lifesciences
- Biogenomics Limited
- Endocrine Technologies, Inc.
- Accurate Chemical & Scientific Corporation
- Spectrum Chemical Mfg. Corp.
- Alfa Chemical Corp.
- Sekisui Diagnostics LLC
- Biocon
- Sanofi-Aventis
- Lilly
- Novo Nordisk A/S
- Trumac Healthcare
- ADOCIA
- Gan & Lee Pharmaceuticals
- Lupin Ltd.
- WOCKHARDT
- Pfizer Inc.
- Cipla Inc.
- Loka Biosciences
- Others

第 12 章：360 度分析師視角

第 13 章：附錄

研究方法
參考
縮寫
免責聲明
聯絡我們

簡介目錄

Product Code: ANV4356

REPORT HIGHLIGHT

Insulin glargine market size was valued at USD 1,820.98 Million in 2023, expanding at a CAGR of 6.50% from 2024 to 2032.

Insulin glargine is a long-acting basal insulin analog used to help control blood sugar levels in individuals with diabetes. Unlike rapid-acting insulins, insulin glargine provides a steady release of insulin over approximately 24 hours, minimizing peaks and reducing the risk of blood sugar fluctuations. It is typically administered once daily, offering convenience and sustained blood sugar control, and is especially beneficial for patients with type 1 or type 2 diabetes requiring consistent insulin levels.

Insulin Glargine Market- Market Dynamics

Increasing incidence of diabetes worldwide to propel market demand

The global insulin glargine market is driven by the rising prevalence of type 2 diabetes, with 537 million adults diagnosed globally. The growing elderly population further increases demand for insulin therapies. Opportunities arise from government healthcare initiatives and the availability of biosimilars. Moreover, the development of more advanced insulin delivery systems, such as smart insulin pens and pumps, offers a more convenient and precise way to administer insulin glargine. However, the complex manufacturing process and supply chain disruptions, like semiconductor shortages, hinder growth.

Insulin Glargine Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.50% over the forecast period (2024-2032)

Based on type segmentation, lantus was predicted to show maximum market share in the year 2023

Based on diabetes type segmentation, type 2 diabetes was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Insulin Glargine Market- Segmentation Analysis:

The Global Insulin Glargine Market is segmented on the basis of Type, Diabetes Type, Distribution Channell, and Region.

The market is divided into three categories based on type: basaglar, lantus, soliqua/suliqua, toujeo, and others. The lantus sector dominates the market. This is majorly due to its established efficacy as a long-acting insulin solution and widespread patient and physician preference. Its popularity is further supported by extensive clinical usage and strong brand recognition.

The market is divided into two categories based on diabetes type: type 1 diabetes and type 2 diabetes. The type 2 sector dominates the market and is likely to maintain its dominance during the forecast period. This growth is driven by the rising prevalence of type 2 diabetes worldwide, fueled by factors such as aging populations, urbanization, and lifestyle changes.

Insulin Glargine Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Insulin Glargine Market- Competitive Landscape:

The insulin glargine market is expanding due to the rising demand for long-acting insulin solutions. Companies are focusing on improving product formulations to enhance patient compliance and minimize side effects. Additionally, competitive strategies include partnerships and collaborations to broaden distribution networks, as well as investment in biosimilar development to offer cost-effective alternatives. Some firms are also focusing on digital health integrations to provide comprehensive diabetes management solutions, targeting long-term user engagement.

Recent Developments:

In April 2024, Sanofi India announced the launch of Soliqua, a new diabetes treatment for adults with type 2 diabetes and obesity. Approved by CDSCO, it helps improve glycemic control alongside diet and exercise.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INSULIN GLARGINE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Amigoz Lifesciences
Biogenomics Limited
Endocrine Technologies, Inc.
Accurate Chemical & Scientific Corporation
Spectrum Chemical Mfg. Corp.
Alfa Chemical Corp.
Sekisui Diagnostics LLC
Biocon
Sanofi-Aventis
Lilly
Novo Nordisk A/S
Trumac Healthcare
ADOCIA
Gan & Lee Pharmaceuticals
Lupin Ltd.
WOCKHARDT
Pfizer Inc.
Cipla Inc.
Loka Biosciences
Others

GLOBAL INSULIN GLARGINE MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

Basaglar
Lantus
Soliqua/Suliqua
Toujeo
Others

GLOBAL INSULIN GLARGINE MARKET, BY DIABETES TYPE- MARKET ANALYSIS, 2019 - 2032

Type 1 Diabetes
Type 2 Diabetes

GLOBAL INSULIN GLARGINE MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Online Pharmacies
Retail Pharmacies
Hospital Pharmacies

GLOBAL INSULIN GLARGINE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Insulin Glargine Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Insulin Glargine Market Snippet by Type
- 2.1.2. Insulin Glargine Market Snippet by Diabetes Type
- 2.1.3. Insulin Glargine Market Snippet by Distribution Channel
- 2.1.4. Insulin Glargine Market Snippet by Country
- 2.1.5. Insulin Glargine Market Snippet by Region
2.2. Competitive Insights

3. Insulin Glargine Key Market Trends

3.1. Insulin Glargine Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Insulin Glargine Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Insulin Glargine Market Opportunities
3.4. Insulin Glargine Market Future Trends

4. Insulin Glargine Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Insulin Glargine Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Insulin Glargine Market Landscape

6.1. Insulin Glargine Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Insulin Glargine Market - By Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
- 7.1.2. Basaglar
- 7.1.3. Lantus
- 7.1.4. Soliqua/Suliqua
- 7.1.5. Toujeo
- 7.1.6. Others

8. Insulin Glargine Market - By Diabetes Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Diabetes Type, 2023 & 2032 (%)
- 8.1.2. Type 1 Diabetes
- 8.1.3. Type 2 Diabetes

9. Insulin Glargine Market - By Distribution Channel

9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
- 9.1.2. Online Pharmacies
- 9.1.3. Retail Pharmacies
- 9.1.4. Hospital Pharmacies

10. Insulin Glargine Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Insulin Glargine Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Insulin Glargine Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.8. Italy
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.8.4. Italy Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.9. United Kingdom
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.9.4. United Kingdom Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.10. France
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.10.4. France Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.11. Russia
  - 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.11.3. Russia Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.12. Netherlands
  - 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.12.3. Netherlands Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.14. Poland
  - 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.14.3. Poland Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.15. Rest of Europe
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Rest of the Europe Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Insulin Glargine Key Manufacturers in Asia Pacific
- 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.5. Asia Pacific Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
- 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.7. India
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.7.4. India Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.8. China
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.8.4. China Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.12. Thailand
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Thailand Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.13. Indonesia
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Indonesia Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5. Latin America
- 10.5.1. Overview
- 10.5.2. Insulin Glargine Key Manufacturers in Latin America
- 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.5.5. Latin America Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
- 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
- 10.6.1. Overview
- 10.6.2. Insulin Glargine Key Manufacturers in Middle East and Africa
- 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.5. Middle East and Africa Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
- 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.8. United Arab Emirates
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.8.4. United Arab Emirates Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Insulin Glargine Industry

11.1. Competitive Dashboard
- 11.1.1. Competitive Benchmarking
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. Amigoz Lifesciences
- 11.2.2. Biogenomics Limited
- 11.2.3. Endocrine Technologies, Inc.
- 11.2.4. Accurate Chemical & Scientific Corporation
- 11.2.5. Spectrum Chemical Mfg. Corp.
- 11.2.6. Alfa Chemical Corp.
- 11.2.7. Sekisui Diagnostics LLC
- 11.2.8. Biocon
- 11.2.9. Sanofi-Aventis
- 11.2.10. Lilly
- 11.2.11. Novo Nordisk A/S
- 11.2.12. Trumac Healthcare
- 11.2.13. ADOCIA
- 11.2.14. Gan & Lee Pharmaceuticals
- 11.2.15. Lupin Ltd.
- 11.2.16. WOCKHARDT
- 11.2.17. Pfizer Inc.
- 11.2.18. Cipla Inc.
- 11.2.19. Loka Biosciences
- 11.2.20. Others